RecruitingPhase 2NCT06462547

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Studying Pseudoxanthoma elasticum

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Inozyme Pharma
Principal Investigator
Kurt Gunter, MD
Inozyme Pharma, Inc.
Intervention
INZ-701(drug)
Enrollment
200 enrolled
Eligibility
1 years · All sexes
Timeline
2024 – 2030

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06462547 on ClinicalTrials.gov

Other trials for Pseudoxanthoma elasticum

Additional recruiting or active studies for the same condition.

See all trials for Pseudoxanthoma elasticum →

← Back to all trials